Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BS-006
- Development stage
- Phase 2
- Lead developer
- Wuhan Binhui Biopharmaceutical
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Oncolytic Viruses → Oncolytic Therapeutics, Vaccines & Immunotherapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules, Recombinant Proteins and Enzymes
- Administration
- Intratumoral
01
Overview
BS-006 is an engineered recombinant oncolytic type II herpes simplex virus (HSV2) developed by Wuhan Binhui Biopharmaceutical. It is designed to selectively infect and lyse tumor cells while sparing normal tissue. The virus has been genetically modified by deleting the ICP34.5 and ICP47 genes, which enhances safety and immune activation in normal cells. Additionally, BS-006 expresses a bispecific T cell engager antibody targeting both CD3 (on T cells) and PD-L1 (on tumor or immune cells), aiming to redirect T cell cytotoxicity toward tumor cells and relieve immunosuppression within the tumor microenvironment. The drug is administered via intratumoral injection and is currently in Phase I clinical trials for multiple solid tumors, including cutaneous squamous cell carcinoma, melanoma, breast cancer, cervical cancer, and other advanced or metastatic solid tumors[1][2][3][4][5].
- Other names
- Recombinant oncolytic type II herpes simplex virus -Binhui Biopharmaceutical
02
Targets
CD3 (T-cell surface glycoprotein CD3)CD274 (Programmed cell death protein 1 ligand 1)
Beyond the preview
Go deeper on BS-006.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BS-006.